Trexquant Investment LP Buys 75,392 Shares of Illumina, Inc. $ILMN

Key Points

• Trexquant Investment LP increased its ownership in Illumina, Inc. by 52.7% during the 1st quarter, acquiring an additional 75,392 shares to bring its total to 218,369 shares, valued at approximately $17.3 million.
• Illumina reported $1.19 EPS for the last quarter, surpassing analysts' expectations of $1.02, despite a 4.8% year-over-year revenue decline to $1.06 billion.
• According to recent analyst ratings, the stock has a consensus rating of "Hold" with an average target price of $123.17, reflecting varying perspectives on its future performance.

Trexquant Investment LP raised its stake in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 52.7% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 218,369 shares of the life sciences company's stock after purchasing an additional 75,392 shares during the quarter. Trexquant Investment LP owned 0.14% of Illumina worth $17,325,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in ILMN. Diversified Trust Co purchased a new stake in Illumina during the first quarter worth about $355,000. State of Alaska Department of Revenue increased its stake in shares of Illumina by 2.5% during the 1st quarter. State of Alaska Department of Revenue now owns 18,527 shares of the life sciences company's stock valued at $1,469,000 after acquiring an additional 445 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Illumina by 4.9% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 199,176 shares of the life sciences company's stock valued at $15,803,000 after buying an additional 9,252 shares during the period. Merit Financial Group LLC grew its position in Illumina by 344.8% during the first quarter. Merit Financial Group LLC now owns 13,036 shares of the life sciences company's stock valued at $1,034,000 after acquiring an additional 10,105 shares during the period. Finally, Citigroup Inc. lifted its position in Illumina by 13.5% during the first quarter. Citigroup Inc. now owns 150,764 shares of the life sciences company's stock valued at $11,962,000 after buying an additional 17,985 shares in the last quarter. Institutional investors and hedge funds own 89.42% of the company's stock.

Illumina Stock Performance

NASDAQ:ILMN traded down $1.73 during midday trading on Wednesday, reaching $96.09. The stock had a trading volume of 445,093 shares, compared to its average volume of 2,290,085. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.81 and a quick ratio of 1.41. The firm's fifty day simple moving average is $99.42 and its 200-day simple moving average is $88.53. The stock has a market capitalization of $14.77 billion, a P/E ratio of 12.16, a PEG ratio of 2.25 and a beta of 1.43. Illumina, Inc. has a 1-year low of $68.70 and a 1-year high of $156.66.

Illumina (NASDAQ:ILMN - Get Free Report) last announced its quarterly earnings data on Thursday, July 31st. The life sciences company reported $1.19 EPS for the quarter, beating analysts' consensus estimates of $1.02 by $0.17. The business had revenue of $1.06 billion during the quarter, compared to analyst estimates of $1.12 billion. Illumina had a net margin of 29.36% and a return on equity of 28.93%. The firm's revenue for the quarter was down 4.8% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.36 earnings per share. Illumina has set its FY 2025 guidance at 4.450-4.55 EPS. On average, equities research analysts forecast that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts recently issued reports on ILMN shares. Piper Sandler dropped their price target on shares of Illumina from $190.00 to $185.00 and set an "overweight" rating on the stock in a research note on Thursday, May 15th. Robert W. Baird boosted their price objective on shares of Illumina from $84.00 to $105.00 and gave the company a "neutral" rating in a research report on Monday, July 28th. Barclays raised their target price on Illumina from $85.00 to $90.00 and gave the company an "underweight" rating in a research note on Friday, August 1st. Canaccord Genuity Group lifted their target price on Illumina from $99.00 to $105.00 and gave the company a "hold" rating in a research note on Friday, August 1st. Finally, Scotiabank lowered shares of Illumina from a "sector outperform" rating to a "sector perform" rating and set a $125.00 price objective on the stock. in a research note on Friday, July 11th. Six investment analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and two have issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Hold" and an average target price of $123.06.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.